Core Viewpoint - The core strategy of Minsheng Health is centered around continuous innovation, leveraging a dual approach of "century-old pharmaceutical company + innovation engine" to drive strategic upgrades in the context of the "Healthy China 2030" initiative [1][2]. Group 1: Four New Strategies - Minsheng Health has introduced a "Four New" strategy focusing on new products, new models, new businesses, and new projects to adapt to the rapidly changing market environment and intense industry competition [2][3]. - The company emphasizes that innovation is the core driving force, with a focus on product innovation that enhances both functionality and user experience [2][3]. - The product matrix has expanded significantly, exemplified by the evolution of the classic 21 Jin Weita product from a single SKU to over fifty targeted at specific consumer segments [2][3]. Group 2: New Business Development - Minsheng Health is enhancing its industry chain layout through mergers and acquisitions, with a planned acquisition of a strain raw material company in 2024 to strengthen its position in the probiotic sector [2][3]. - The company aims to ensure raw material supply for its proprietary products while providing comprehensive solutions to major brands through OEM/ODM models [2][3]. Group 3: New Model Exploration - The company has made significant adjustments to its sales channels and organizational structure, allowing for flexibility and rapid response to market changes [3]. - Minsheng Health maintains a principle of expanding into related fields, ensuring that all new businesses, projects, and models revolve around product innovation [3]. Group 4: Probiotic Market Focus - With the Chinese probiotic market exceeding 100 billion yuan, Minsheng Health views its probiotic business as a key growth driver, leveraging its "Yanhuang Strain Resource Library" and advanced technology systems [3][4]. - The company has developed a precise and efficient efficacy expression technology system, enhancing the survival and colonization rates of strains in the body [4]. Group 5: Capital Market Impact - The successful listing of Minsheng Health in 2023 has led to a fundamental change in the company's operations, promoting standardized development and compliance [5][6]. - The listing has diversified employee incentive methods, allowing for more comprehensive team motivation strategies [5][6]. - The company sees greater opportunities for business expansion and mergers post-listing, although it remains cautious in selecting high-quality partners for acquisitions [6]. Group 6: Future Outlook - Minsheng Health plans to continue increasing R&D investment in targeted health solutions, focusing on weight management, gut-brain axis regulation, and anti-aging [5]. - The company aims to maintain strategic determination and continue innovating while ensuring effective team succession and cultural continuity [6].
四新策略驱动百年药企迈向高质量发展